Assay will predict which patients are best suited to the therapeutic that targets the steroid sulfatase enzyme.
bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug candidate. The assay is intended for both the clinical development of the compound as well as a diagnostic test potentially for future commercialization.
BN 83495 is designed to block the steroid sulfatase enzyme (STS), which is found in hormone-dependent breast cancer in postmenopausal women. bioMérieux will devise a tool to determine the patients best suited to benefit from this STS inhibitor.
The test will be developed on bioMérieux’ NucliSENS EasyQ® molecular diagnostics platform, using the NASBA® amplification technology. The company will will co-fund the project with Ipsen.
